# Ingenol Mebutate (Picato®) With Methyl Aminolevulinate Photodynamic Therapy for the Treatment of Actinic Keratosis

> **NCT02354391** · PHASE2 · UNKNOWN · sponsor: **Pacific Dermaesthetics** · enrollment: 20 (estimated)

## Conditions studied

- Actinic Keratosis

## Interventions

- **DRUG:** Ingenol mebutate Picato® and MAL PDT day 1, day 5
- **DRUG:** Ingenol mebutate Picato® day 2, 3, 4
- **PROCEDURE:** MAL PDT day 5

## Key facts

- **NCT ID:** NCT02354391
- **Lead sponsor:** Pacific Dermaesthetics
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-01
- **Primary completion:** 2019-12
- **Final completion:** 2019-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2019-03-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02354391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02354391, "Ingenol Mebutate (Picato®) With Methyl Aminolevulinate Photodynamic Therapy for the Treatment of Actinic Keratosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02354391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*